<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> and reactivation is an increasing complication in immune deficient patients, particularly after allogeneic hematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Therapy with anti-thymocyte globulin (ATG) is associated with higher incidence of EBV-related disease in HSCT patients, but this risk is not documented in patients receiving ATG for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) </plain></SENT>
<SENT sid="2" pm="."><plain>We describe the case of a patient who developed an <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e>, with the clinical features of an <z:e sem="disease" ids="C0021345" disease_type="Disease or Syndrome" abbrv="">infectious mononucleosis</z:e>, after immune suppression with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> and two courses of ATG for SAA </plain></SENT>
</text></document>